

Revision date: 04-Jan-2007

Version: 1.1

Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Emergency telephone number: ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Tenitramine Tablets

Trade Name:	Tinitran 10
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product for the treatment of angina pectoris

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Tenitramine	21946-79-2	Not listed	10 mg***
Corn Starch	9005-25-8	232-679-6	*
Microcrystalline cellulose	9004-34-6	232-674-9	*
Silicon dioxide, colloidal NF	7631-86-9	231-545-4	*

Additional Information:

* Proprietary

*** per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Signal Word:	White tablets WARNING
Statement of Hazard:	May be harmful if swallowed.
Additional Hazard Information: Short Term: Known Clinical Effects:	Accidental ingestion may cause effects similar to those seen in clinical use. Due to intended use, dangerous lowering of blood pressure can occur. Headache, which may be severe and persistent, may occur immediately after use. Vertigo, dizziness, weakness, palpitation, and other manifestations of postural hypotension may develop occasionally. Flushing, drug rash, and exfoliative dermatitis have been reported in patients receiving nitrate therapy.
EU Indication of danger:	Harmful

EU Hazard Symbols:



EU Risk Phrases:

R22 - Harmful if swallowed.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact:	Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.
Skin Contact:	Wash skin with soap and water. If irritation occurs or persists, get medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media:	Use carbon dioxide, dry chemical, or water spray.
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.
Fire / Explosion Hazards:	Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling:	If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing.
Storage Conditions:	No special precautions required.
8. EXPOSURE CONTROLS / PERSONAL PROTECTION	

Material Name: Tenitramine Tablets Revision date: 04-Jan-2007

Corn Starch			
OSHA - Final PELS - TWAS		= 15 mg/m³ TWA total = 5 mg/m³ TWA	
ACGIH Threshold Limit Val Australia TWA	ue (TWA)	= 10 mg/m ³ TWA = 10 mg/m ³ TWA	
Microcrystalline cellulose			
OSHA - Final PELS - TWAS		= 15 mg/m³ TWA total = 5 mg/m³ TWA	
ACGIH Threshold Limit Val Australia TWA	ue (TWA)	= 10 mg/m ³ TWA = 10 mg/m ³ TWA	
Silicon dioxido, colloidal NE			
Silicon dioxide, colloidal NF OSHA - Final PELs - Table Z-3 Mineral D:		(80)/(% SiO2) mg/m³ TWA = 20 mppcf TWA	
Australia TWA		= $2 \text{ mg/m}^3 \text{ TWA}$	
The exposure limit(s) listed for solid components are only relevant if dust may be generated.			
Engineering Controls:	Engineering controls should be used as the primary means to control exposures.		
Personal Protective Equipment:			
Hands:	Not required for the normal use of this product. Wear protective gloves when working with large quantities.		
Eyes:	Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.		
Skin:	Not required for the normal use of this product. Wear protective clothing when working with large guantities.		
Respiratory protection:	Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.		

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Tablet	Color:	White
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY

Stability:Stable underConditions to Avoid:NoneIncompatible Materials:None	normal conditions of use.
---	---------------------------

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Microcrystalline cellulose

Material Name: Tenitramine Tablets Revision date: 04-Jan-2007

Page 4 of 6 Version: 1.1

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Tenitramine

 Mouse
 Oral
 LD 50
 335
 mg/kg

 Rat
 Intraperitoneal
 LD 50
 122
 mg/kg

 Acute Toxicity Comments:
 A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Tenitramine

6 Month(s) Rat Oral 2 mg/kg/day NOAEL None identified 6 Month(s) Rabbit Oral 0.5 mg/kg/day NOAEL None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Tenitramine

Fertility and Embryonic Development Fertility and Embryonic Development Fertility and Embryonic Development	Mouse Oral 0.5 mg/kg/day NOEL No effects at maximum dose Rat Oral 0.5 mg/kg/day NOEL No effects at maximum dose Rabbit Oral 0.5 mg/kg/day NOEL No effects at maximum dose
Carcinogen Status:	None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below
Silicon dioxide, colloidal NF IARC:	Group 3

12. ECOLOGICAL INFORMATION	

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: EU Indication of danger:	Xn Harmful
EU Risk Phrases:	R22 - Harmful if swallowed.
EU Safety Phrases:	S22 - Do not breathe dust.

OSHA Label: WARNING May be harmful if swallowed.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 1, Subdivision B



Corn Starch Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	XU Present 232-679-6
Microcrystalline cellulose Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	XU Present 232-674-9
Silicon dioxide, colloidal NF Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS List	Present Present 231-545-4

16. OTHER INFORMATION

Reasons for Revision:	Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations.
Prepared by:	Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet